Latest Content

Kenco has put DeepFabric's AI agents into live production across its 3PL operations, with plans to scale to 20 agents within a year.

Serialization data does more than meet DSCSA rules. See how connected event histories improve recalls, returns and inventory visibility.

Nick Niemeyer of API Innovation Center on how the National Fragility Index could help reduce US drug shortage risk.

Four pharma experts discuss industry trends in M&A, direct-to-patient sales, patient access and commercial strategy at the H1 midyear mark.

The Section 232 tariff deadline for 17 major drugmakers has arrived. Here's what pharma supply chain teams need to know now.

Domestic manufacturing can reduce certain dependencies, but reliable pharmaceutical commercialization requires qualified redundancy, sustainable economics, quality maturity and decision-ready visibility across the full supply network.

Access leaders are pressed to prove AI ROI, but ConnectiveRx execs Cindy Baksh and Steve Randall argue the real work is defining "better" first, then deciding where AI fits.

In this week's Pharma Pulse, Infinitus launches an AI-first hub model, EVERSANA is tapped to commercialize Innovacell's regenerative cell therapy in the US, Peli BioThermal and PAXAFE pair packaging with predictive cold chain intelligence, and Ember LifeSciences strikes a distribution alliance with Japan's top pharma wholesaler.

Ember LifeSciences and Alfresa, Japan's top pharma wholesaler, form a cold chain alliance as biologics and specialty distribution demand grows.

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Gifthealth's Chip Parkinson says direct-to-patient adoption has accelerated since January, driven by structural, not cyclical, market forces.

Peli BioThermal and PAXAFE are partnering to pair cold chain packaging with AI-powered monitoring, signaling where pharma logistics technology is headed next.

Gifthealth's Chip Parkinson revisits his 2026 outlook on the direct-to-patient model, and what's developed in H1.